triazolam has been researched along with Paranoia in 2 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klett, CJ | 1 |
| Schogt, B | 1 |
| Conn, D | 1 |
1 review available for triazolam and Paranoia
| Article | Year |
|---|---|
Review of triazolam data.
Topics: Age Factors; Aged; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Ph | 1992 |
1 other study available for triazolam and Paranoia
| Article | Year |
|---|---|
Paranoid symptoms associated with triazolam.
Topics: Aged; Female; Humans; Paranoid Disorders; Triazolam | 1985 |